Company Overview and News
Chicago, IL – September 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Ingersoll-Rand Plc (IR - Free Report) , Endo International plc (ENDP - Free Report) , Glanbia plc (GLAPY - Free Report) and Smurfit Kappa Group plc (SMFKY - Free Report) .
IR.WI GLAPY IR SKG SMFKY ENL INGERRAND ENDP 500210
The U.S. manufacturing activity has picked up tempo as exhibited by the stellar performance of Institute for Supply Management (ISM) index in August 2018. The index increased 3.2% from July to 61.3% in August — the highest reading since 2004. This was driven by strong demand for U.S. manufacturing goods, the Tax Cuts and Jobs Act, which has helped to overcome the hurdles like supply chain bottlenecks, rising input prices, shortage of skilled labourers and global trade uncertainties.
IR.WI TWIN IR IEX INGERRAND FLS 500210
Per the latest report by Ireland’s Central Statistics Office on Sep 13, the fastest-growing economy of the European Union surged beyond expectations in the second quarter. Growth was buoyed by a steady increase in technology exports. With unemployment already near a 10-year low, the country has witnessed strength in its service sector as well as household spending.
IR.WI CY GLAPY IR SKG SMFKY ENL INGERRAND ENDP 500210
U.S. manufacturing business continues to gather steam amid tariff-related uproar rooted by President Trump and other overseas countries, including China. Per the Institute for Supply Management (ISM) survey, the Purchasing Managers Index clocked its best gain since 2004 in August this year. The remarkable expansion was primarily backed by growth in orders, production and employment.
IR.WI TWIN IR LXFR ALG INGERRAND CMCO 500210
NCI Building Systems, Inc. (NCS - Free Report) : This company that designs, engineers, manufactures, and markets metal products has seen the Zacks Consensus Estimate for its current year earnings increasing 3.6% over the last 60 days.
IR.WI GJT BLT BHPBF NCS ALL BHP IR BBL BHP INGERRAND BHPLF 500210
We believe that Ingersoll-Rand plc (IR - Free Report) is a solid choice for investors seeking exposure in the industrial machinery space. The stock, with roughly $25-billion market capitalization, has been upgraded to a Zacks Rank #1 (Strong Buy) on Aug 30. Moreover, the stock’s investment appeal is accentuated by a favorable VGM Score of B. The company delivered better-than-expected results in three out of the last four quarters, with an average positive earnings surprise of 5.
IR.WI AIMC IR B CFX INGERRAND 500210
The Invesco Zacks Mid-Cap ETF (CZA - Free Report) made its debut on 04/02/2007, and is a smart beta exchange traded fund that provides broad exposure to the Mid Cap ETFs category of the market.
IR.WI BGX ETP IR BGLF BX INGERRAND 500210 BGB
U.S. GDP growth tapped the best gain in the past four years during the April-June quarter. Solid business and consumer spending, along with growth in exports, helped drive economic growth in the country.
IR.WI HD ADES AIMC IR ALG INGERRAND 500210
Good morning. My name is Virgil and I will be your conference operator today. At this time I would like to welcome everyone to the Ingersoll Rand Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question and answer session. Thank you. Zac Nagle, Vice President of Investor Relations, you may begin your conference.
IR.WI IR INGERRAND 500210
With a diverse portfolio of industrial and commercial products, Ingersoll-Rand Plc (IR - Free Report) is a premier player in the industrial goods market. This Dublin, Ireland-based firm has a solid foundation of global brands with a leading market share in all major product lines. After the divestiture of the commercial and residential security businesses, IR has been diligently focusing on improving the efficiencies and capabilities of its core businesses.
IR.WI IR MS INGERRAND 500210
Ingersoll-Rand Plc (IR - Free Report) is scheduled to report second-quarter 2018 results on Jul 25, before the market opens. The company pulled off an average positive earnings surprise of 3.91%, over the last four quarters. Notably, in the last reported quarter, Ingersoll-Rand’s earnings of 70 cents per share surpassed the Zacks Consensus Estimate by 12.9%. The Estimate for the to-be-reported quarter is pegged at $1.
IR.WI GGG IR ATKR INGERRAND ETN 500210
June ISM manufacturing index witnessed the best gain in the four months amid trade war anxieties. This call for bets on top-ranked manufacturing stocks.
IR.WI SKUFF TACO WIRE KAMN IRET TKR ZBRA TWNK TACOW IR WRD INGERRAND DHR 500210 MO
Launched on 04/02/2007, the Invesco Zacks Mid-Cap ETF (CZA - Free Report) is a smart beta exchange traded fund offering broad exposure to the Mid Cap ETFs category of the U.S. equity market.
IR.WI BGX IR BGLF BX INGERRAND NUE 500210 BGB
CHICAGO, June 25 (Reuters) - From global manufacturers such as Harley-Davidson Inc to small tech startups, companies are scrambling to rework supply chains built for an era of stable, open trade policy that is now under threat.
IR.WI DDAIF SCS IR MS INGERRAND 500210
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...